Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OPNT Opiant Pharmaceuticals (OPNT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Opiant Pharmaceuticals Stock (NASDAQ:OPNT) 30 days 90 days 365 days Advanced Chart Ad DarwinHow Low-Cost Stocks Generate Monthly IncomeAre you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!👉 Yes, I Want the Free Report! 👈 Get Opiant Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$20.03▼$21.1052-Week Range N/AVolume562,700 shsAverage Volume77,920 shsMarket Capitalization$108.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOpiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.Read More… Receive OPNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address OPNT Stock News HeadlinesMovers From YesterdayOctober 10, 2024 | benzinga.comCNFinance Hldgs (NYSE:CNF) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comForced out of retirement by these trades You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changedDecember 26, 2024 | DTI (Ad)Hikma Pharmaceuticals PLC ADR (HKMPY)April 18, 2024 | investing.comIonis PharmaceuticalsJanuary 31, 2024 | forbes.comUPDATE 2-US FDA approves Opiant's spray for reversing opioid-related overdosesMay 24, 2023 | msn.comREFILE-US FDA approves Opiant's overdose reversal sprayMay 23, 2023 | msn.comIndivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science PortfolioMarch 3, 2023 | msn.comSee More Headlines OPNT Stock Analysis - Frequently Asked Questions How were Opiant Pharmaceuticals' earnings last quarter? Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) posted its quarterly earnings data on Thursday, November, 11th. The technology company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.41. The technology company earned $16.34 million during the quarter, compared to analysts' expectations of $12.45 million. Opiant Pharmaceuticals had a negative trailing twelve-month return on equity of 97.03% and a negative net margin of 147.90%. What other stocks do shareholders of Opiant Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Opiant Pharmaceuticals investors own include NIO (NIO), Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), Cara Therapeutics (CARA), Dynavax Technologies (DVAX) and AcelRx Pharmaceuticals (ACRX). Company Calendar Last Earnings11/11/2021Today12/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OPNT CUSIPN/A CIK1108924 Webwww.opiant.com Phone(310) 598-5410Fax917-322-2105Employees37Year Founded2009Profitability EPS (Most Recent Fiscal Year)($6.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3.01 million Net Margins-147.90% Pretax Margin-147.84% Return on Equity-97.03% Return on Assets-59.66% Debt Debt-to-Equity Ratio0.60 Current Ratio5.48 Quick Ratio5.48 Sales & Book Value Annual Sales$47.78 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow24.75 Book Value$9.92 per share Price / BookN/AMiscellaneous Outstanding Shares5,270,000Free Float3,865,000Market Cap$108.83 million OptionableNot Optionable Beta0.84 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:OPNT) was last updated on 12/26/2024 by MarketBeat.com Staff From Our PartnersTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opiant Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opiant Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.